Italia Markets open in 3 hrs 22 mins

Novo Nordisk A/S (0QIU.L)

YHD - YHD Prezzo differito. Valuta in USD.
Aggiungi a watchlist
114.191.998.976,00+19,80 (+0,00%)
Alla chiusura: 06:07PM EDT
Schermo intero
Chiusura precedenteN/D
Rendimento dall'inizio dell'anno (YTD)N/D
Coefficiente di spesa (netto)N/D
Ultimo guadagno in conto di capitaleN/D
Rating di MorningStarN/D
Rating di Morningstar (rischio)N/D
Rating di sostenibilità
Attività netteN/D
Beta (5 anni mensile)N/D
Rendimento medio 5aN/D
Turnover portafoglio titoliN/D
Ultimo dividendoN/D
Media per la categoriaN/D
Data di inizio disponibilitàN/D
  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i

  • GlobeNewswire

    Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial

    Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg an

  • GlobeNewswire

    Resolutions from the Annual General Meeting of Novo Nordisk A/S

    Bagsværd, Denmark, 23 March 2023 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, Chair of the Board of Directors communicated: “We are very pleased with the performance of Novo Nordisk in 2022, where we continued to make progress on our strategic aspirations. Globally, we reached almost 40 million patients, the most ever. As Novo Nordisk celebrates its 100th anniversary in 2023, the need for innovation has never been greater. We will continue